MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1867314

Медицинская библиотека · Frontiers in immunology · 2026

Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders.

Corrao Salvatore, Scibetta Salvatore, Falcone Fabio, Cangemi Ignazio, Corrao Giacomo, Calvo Luigi

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Janus kinase (JAK) inhibitors are approved for several immune-mediated inflammatory disorders (IMIDs), but regulatory agencies, including the European Medicines Agency and the US Food and Drug Administration, have issued class-wide safety warnings regarding major adverse cardiovascular events, venous thromboembolism, and malignancy. Early myocardial effects after selective JAK1 inhibition have not been prospectively evaluated. We assessed cardiovascular safety and myocardial deformation after upadacitinib initiation in a real-world IMID cohort.

METHODS

In this prospective, single-centre, exploratory observational study, 36 consecutive adults with atopic dermatitis, prurigo nodularis, rheumatoid arthritis, or psoriatic arthritis initiating upadacitinib were enrolled. Transthoracic echocardiography with speckle-tracking global longitudinal strain (GLS) was performed at baseline, 1, 3, and 6 months. Echocardiographic operators were blinded to the study hypothesis. Longitudinal changes were analysed using rank-based repeated-measures models.

RESULTS

Thirty-six patients were included (median age 51 years; 55.6% female). Baseline left ventricular ejection fraction (LVEF) was preserved (median 56.0%, IQR 55.0-61.0), whereas GLS suggested subclinical myocardial dysfunction (-18.4%, IQR -19.8 to -16.2). No significant longitudinal changes were observed in LVEF (p=0.789), left ventricular mass index, relative wall thickness, or epicardial fat thickness, indicating no early structural or systolic harm. GLS showed a significant overall time effect (p=0.003), with a favourable trajectory at 1 month (p=0.003), sustained at 3 months (p=0.007) and 6 months (p=0.007). E/e' increased modestly at 6 months (p=0.008) without structural remodelling.

CONCLUSIONS

Upadacitinib initiation was not associated with early myocardial harm and showed a reassuring cardiovascular profile. A favourable GLS trajectory without LVEF change is hypothesis-generating and requires confirmation in adequately powered controlled studies.

Для цитирования: Corrao Salvatore, Scibetta Salvatore, Falcone Fabio, Cangemi Ignazio, Corrao Giacomo, Calvo Luigi. Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1867314.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.